March 13: This post has been corrected.
When Dollars
for Docs first launched in 2010, ProPublica
spoke with several of the dozens of doctors who had earned
more than $200,000 from their speaking and consulting work for drug companies.
Now, with records from more companies and more years of data, we’ve identified 22 doctors who’ve earned at
least $500,000 since 2009 — including one, Jon Draud, who was paid more
than $1 million.
Most of these
in-demand speakers hail from a just handful of states: four each from New York
and Texas, and two each from California, Massachusetts, Pennsylvania and
Tennessee. Half are psychiatrists, including three of the top four earners. The
most commonly represented drug companies are Merck and Pfizer — 15 of the
22 doctors speak or consult for each of them. And all but one of the doctors are men.
Amounts listed
below are for speaking and consulting only; compensation for travel, meals,
research and other categories is excluded. The disclosures include payments to
doctors dating back to 2009 for many drug companies, though others do not go
back as far. If the recipients have
separately disclosed relationships with drug companies that are not in Dollars
for Docs, they are noted.
Location:
Nashville, Tenn.
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Kentucky, Class of 1990
Amount: $1,009,213
Companies:
AstraZeneca, Cephalon, Eli Lilly, Forest, Merck, Novartis, Pfizer
Draud, the
medical director of the Psychiatric Hospitalist Program at Baptist Hospital and
Middle Tennessee Medical Center, stated in a conference biography in 2010 that
he has “delivered over 3,500 professional lectures to medical personnel.” Draud previously has disclosed financial relationships
with Angelini-Biopharm, Sanofi-Aventis, Sunovion and Takeda. He did not respond to requests for
comment.
Location: Santa
Monica, Calif.
Board Certification: American Board of Anesthesiology
Medical School:
University of Massachusetts, Class of 1983
Amount: $730,400
Companies: Cephalon,
Johnson & Johnson, Eli Lilly, Pfizer
Sacks specializes in pain management. He declined to comment about his
speaking when reached by ProPublica in March. He previously has disclosed a financial relationship with Abbott Laboratories.
Location: Exeter,
N.H.
Board Certification: American Board of Psychiatry and Neurology
Medical School: University of Massachusetts, Class of 1986
Amount: $669,935
Companies: AstraZeneca,
Forest, Pfizer
Miller is the medical
director of Brain Health. He is also a staff psychiatrist at Seacoast Mental
Health Center and a consulting
psychiatrist at Exeter Hospital. Miller previously disclosed a financial relationship
with Sunovion. He did not respond to repeated requests
for comment.
Location: Costa
Mesa, Calif.
Board Certification: American Board of Psychiatry and Neurology
Medical School: Autonomous University of Guadalajara, Class of 1990
Amount: $663,751
Companies: AstraZeneca,
Forest, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer
Alva is the
medical director of ATP
Clinical Research, a private clinical research company
specializing in neuropsychiatric investigations. He previously served as assistant clinical professor of psychiatryat the University of California, Irvine. Reached about his speaking, Alva told ProPublica, “I actually enjoy
the aspect of educating my counterparts about developments in the field.”
Location:
Philadelphia, Pa.
Medical School: Dr.
William M. Scholl College of Podiatric Medicine, Class of 1981
Amount: $652,412
Companies: Merck,
Pfizer, Valeant
Joseph is a
podiatrist at Roxborough Memorial Hospital in Philadelphia.
He is editor of the Journal of the American Podiatric Medical Association and a fellow of the Infectious Diseases Society of America. “Yes, I go out and spread this information to my colleagues and it is often paid for by industry,” Joseph said in an email to ProPublica, referring to diabetes research conducted in the private sector, including by pharmaceutical companies. “However, by doing so I know I have saved countless limbs and lives. Frankly, I don’t see anything nefarious about that.”
Location: Gardner,
Mass.
Board Certification: American Board of Allergy and Immunology
Medical School:
Northwestern University, Class of 1978
Amount: $651,524
Companies: AstraZeneca,
GlaxoSmithKline, Merck, Novartis
In 2010, DeBuske
resigned from Brigham and Women’s Hospital in Boston because the
Harvard-affiliated teaching hospital had adopted a policy prohibiting its
doctors from speaking on behalf of drug companies, according to the Boston Globe. He did not
respond to requests for comment.
Location:
Cincinnati, Ohio
Board Certification: American Board of Psychiatry and Neurology
Medical School: American University of Beirut, 1972
Amount:
$647,341
Companies:
AstraZeneca, Johnson & Johnson, Novartis, Pfizer
Nasrallah, a
psychiatrist, is an associate dean and professor at
the University of Cincinnati’s College of Medicine, as well as the director of
its schizophrenia program. According to a guest speaker biography for a
University of Arizona psychopharmacology course, Nasrallah served at the chair
of Ohio State University’s psychiatry department for 12 years. Reached by
ProPublica, he declined to comment.
Location:
Grapevine, Texas
Board Certification: American Board of Internal Medicine
Medical School: Jefferson
Medical College of Thomas Jefferson University, Class of 1990
Amount: $622,286
Companies: AstraZeneca,
GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Novartis
John Osborne has a
Ph.D. in cardiovascular physiology from Thomas
Jefferson University. He completed postdoctoral training at Brigham and Women’s
Hospital in Boston. He is the founder and director of State of the Heart
Cardiology and is a faculty member at the
University of Texas at Arlington. Osborne
agreed to a Texas Medical Board order on Feb. 8, 2013, that assessed a $3,000
administrative penalty and subjected his practice to periodic review by an
outside monitor. The order says a nurse in Osborne’s office prescribed
medications for a patient who had not been examined by Osborne or his nurse practitioner.
Osborne
did not respond to requests for comment.
Location: Denver,
Colo.
Medical School: McMaster
University, Class of 1988
Amount: $613,612
Companies: AstraZeneca,
Forest, GlaxoSmithKline, Novartis
Balkissoon specializes in pulmonary disease. He
previously served as an assistant professor at the University of Colorado School of Medicine. Balkissoon previously has disclosed financial relationships with Boehringer Ingelheim and Genentech. He could not be reached for comment.
Location: Lake
Jackson, Texas
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Calcutta
Amount: $582,049
Companies: Forest,
Eli Lilly, Merck, Pfizer
Jain specializes
in psychiatry and serves as director of psychiatric drug research for R/D Clinical Research in Lake Jackson.
Jain previously has disclosed financial relationships
with AstraZeneca, Addrenex, Pamlab, Shionogi, Shire and Sunovion. Reached about
his speaking, Jain told ProPublica, “I am not a marketer, I am an educator.”
Location: Houston,
Texas
Board Certification: American Board of Psychiatry and Neurology
Medical School: University
of Texas at Houston, Class of 1987
Amount: $571,955
Companies: AstraZeneca,
Cephalon, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Novartis, Pfizer
Brams, a
psychiatrist, serves as director of Depelchin Children’s Center and Bayou City Research. Brams also serves as a senior national board examiner for the American Board of Psychiatry and
Neurology. Reached about his speaking, Brams told
ProPublica that companies were interested in his research involving their drugs
and had approached him: “When you’re an investigator, you may be one of only a
handful of doctors who has information on them.”
Location: Durham,
N.C.
Board Certification: American Board of Internal
Medicine
Medical School: University
of Rochester School of Medicine and Dentistry, Class of 1991
Amount: $567,300
Companies:Cephalon, Novartis,GlaxoSmithKline
Rizzieri specializes in cell therapy and
hematologica at Duke Medicine, part of the Duke University Health System, where he completed a
fellowship. Reached by ProPublica, Rizzieri said in an email that he is doing
less industry-sponsored speaking and has refocused his efforts on a program at the
university’s Division of Cellular Therapy called “Duke Debates,” which engages
physicians, nurses and pharmacists in education and research initiatives.
Location: Boston,
Mass.
Board Certification American Board of Internal Medicine
Medical School:
University of Southern California, Class of 1983
Amount: $552,775
Companies:
GlaxoSmithKline, Merck, Pfizer
Nasraway is director of the surgical intensive care unit at Tufts New England Medical Center. He also
serves as an associate professor of Tufts Medical School and has been member of
clinical advisory board at Echo Therapeutics since 2005. He did not respond to requests for comment.
Location: St.
Paul, Minn.
Board Certification: American Board of Anesthesiology
Medical School:
University of Minnesota, Class of 1986
Amount: $542,900
Companies: Forest,
Johnson & Johnson, Eli Lilly, Pfizer
Hess is director
of United Pain Center, a
clinic based at United Hospital in St. Paul that specializes in treating
chronic pain. Reached about his speaking, Hess told ProPublica, “I don’t feel like
I’m a salesman at all. I feel like I’m educating physicians.”
Location: New
York, N.Y.
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Bombay, Class of 1982
Amount: $538,864
Companies: AstraZeneca,
Forest, GlaxoSmithKline, Eli Lilly, Merck, Pfizer
Masand, a
psychiatrist, is the founder and CEO of Global Medical Education, a digital medical education resource. He previously served as
director of therapeutic area development, neurosciences medicine at the Duke Clinical
Research Institute and was a consulting professor of psychiatry and behavioral sciences at Duke
Medical Center. Reached by ProPublica, he declined to
comment.
Location: Suffern, N.Y.
Board Certification: American Board of Psychiatry and Neurology
Medical School: McGill
University, Class of 1983
Amount: $530,569
Companies:
AstraZeneca, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck,
Novartis, Pfizer
Citrome is a
psychiatrist at Good Samaritan Regional
Medical Center in Suffern. He has researched schizophrenia and has
a master’s in public health from Columbia’s Mailman School of Public Health.
Reached by ProPublica, Citrome declined to comment about his speaking work.
Location: Greer,
S.C.
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Belgrade, Class of 1981
Amount: $527,850
Companies:
Cephalon, Eli Lilly, Merck
Maletic
specializes in psychiatry. He completed a residency in psychiatry at the Medical
College of Wisconsin in Milwaukee, followed by a residency in
child psychiatry at Duke University. Reached by ProPublica about his speaking,
Maletic said he believes that “good quality education about pharmaceutical
products may be beneficial to both physicians and their patients.”
Location: Albany,
N.Y.
Board Certification: American Board of Internal Medicine
Medical School:
University of Pennsylvania, Class of 1978
Amount: $527,688
Companies: AstraZeneca,
GlaxoSmithKline, Eli Lilly, Merck, Novartis
Busch is an
endocrinologist. Reached about his speaking by ProPublica, Busch said he gives
about 100 talks a year, most of them in the Northeast. “I don’t know why they
choose me, but they do,” Busch said of the companies that contact him about speaking.
Busch said he has turned down offers to speak about drugs that he doesn’t
endorse, including Avandia, a diabetes drug that remains available
despite a U.S. Food and Drug Administration study that recommended taking it off the market.
Location: Dallas,
Texas
Board Certification: American Board of Internal Medicine
Medical School:
University of Texas at Galveston, Class of 1991
Amount: $516,070
Companies:
GlaxoSmithKline, Johnson & Johnson, Pfizer, Viiv
Race specializes
in infectious disease. Reached about her speaking ProPublica, she said her industry
sponsored work helped pay for trips to train doctors in treating HIV/AIDS and
tuberculosis in South Africa and Belize. “It has been a blessing to do AIDS and
TB work funded by that kind of money,” she said. Race, who was formerly
affiliated with the University of Texas Southwestern,
emphasized that she is now self-employed and is not bound by universityconflict-of-interest policies.
Location: Buffalo,
N.Y.
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Delhi, Class of 1984
Amount: $515,329
Companies:
AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Merck, Novartis
Sanjay Gupta is a
clinical professor at SUNY Upstate Medical University, where he completed his
residency, as well as at SUNY at Buffalo, School of Medicine and Biomedical
Sciences. He was formerly president of Global Research & Consulting, Inc. Gupta
did not return calls from ProPublica. He is not the Sanjay Gupta who is chief medical correspondent for CNN.
Location: Memphis,
Tenn.
Board Certification: American Board of Psychiatry and Neurology
Medical School:
University of Tennessee, Class of 1991
Amount: $512,306
Companies:
AstraZeneca, Forest, Merck, Novartis, Pfizer
Woods practices
with the Psychiatry Group in Memphis. He
did not respond to requests for comment.
Location: Moosic,
Pa.
Medical School: Not Listed
Amount: $504,100
Companies:
AstraZeneca, Cephalon, Forest, GlaxoSmithKline, Johnson & Johnson, Eli
Lilly, Merck, Novartis, Pfizer
Berger, who
specializes in forensic psychiatry, has a practice near Scranton, Pa. Berger’s
office did not respond to requests for comment.
